A Second Trimester and a Working Biologic: Continuing Omalizumab Through Pregnancy
A pregnant woman with severe allergic asthma, well controlled for years on omalizumab, wants to know whether she should stop it now that she's pregnant. The instinct to stop any drug during pregnancy runs directly against what happens to her lungs, and her pregnancy, if she does.
V.P., a 31-year-old accountant, is sixteen weeks into her first pregnancy, a fact that has made her unusually careful about every medication she takes, down to reading the fine print on her prenatal vitamins. She has had severe allergic asthma for most of her adult life and has been stable on omalizumab for four years, with the single worst period of her disease — two hospitalizations in the year before starting it — still vivid enough that she brought it up unprompted before anyone asked.
Her instinct to question every medication during pregnancy is a reasonable one in general, but it runs directly against what the evidence actually says here. Omalizumab is an IgG1 monoclonal antibody, and maternal IgG transfer across the placenta rises steeply through gestation, peaking in the third trimester — which places her, at sixteen weeks, in the stretch where fetal exposure is still comparatively low and where a decision to continue commits her to the higher-transfer months rather than to today's. The actual safety data comes from EXPECT, a prospective pregnancy registry of roughly 250 omalizumab-exposed pregnancies that found no increase in major congenital malformations against a disease-matched comparison cohort; the phrase doing the work there is disease-matched, because the comparison group carried asthma of similar severity, and her own severity is the reason she is on the drug at all — two hospitalizations in the year before starting it, none in the four years since. Set against that reassurance is the well-established alternative risk: poorly controlled asthma during pregnancy is independently associated with preeclampsia, preterm birth, and low birth weight, risks driven by maternal hypoxia during exacerbations rather than by any medication at all.
Her husband, who came with her, mentioned that her mother had a difficult third pregnancy decades ago tied to breathing problems that were never well characterized at the time — which is some of why she arrived with the question already formed, in a pregnancy her obstetric team otherwise calls low-risk, with no gestational diabetes and no hypertension — not a diagnosis anyone can act on today, but part of why she came in wanting a direct answer rather than a vague reassurance.
Joint obstetric-allergy consultation
I'd recommend continuing omalizumab without interruption. EXPECT followed roughly 250 pregnancies with real omalizumab exposure and found no increased signal for major congenital malformations compared to a matched comparison group — that's a meaningfully sized, prospectively collected reassurance, not a small case series. And she has a documented, severe pre-treatment phenotype; this isn't a mild asthmatic where stopping carries little downside.
I agree with continuing, but I want the reasoning stated precisely rather than treating the registry alone as settling it. EXPECT is a real and useful dataset, but it's an observational registry without randomization — women who enroll and continue a biologic during pregnancy may differ systematically from those who don't, and that limits how confidently we can rule out smaller risks. What actually tips this for me is the other side of the ledger: uncontrolled asthma in pregnancy has a well-established, independent association with preeclampsia, preterm birth, and low birth weight, and those risks are not theoretical the way a hypothetical drug signal EXPECT hasn't found would be.
One more piece worth naming precisely so it doesn't get treated as a stopping argument by accident: as an IgG1 antibody, omalizumab's placental transfer increases as pregnancy progresses, most substantially in the third trimester, meaning more of the drug will reach the fetal circulation later in her pregnancy than it does today at sixteen weeks. That's relevant to how the pediatric team should be informed at delivery, not a reason to withhold or reduce the drug now — there's no evidence that increased transfer translates into fetal harm, and the alternative, an undertreated mother, carries the risks the MFM specialist just named with actual epidemiologic weight behind them.
The plan this points to is continuing at her current dose and interval, with the pediatric team informed of biologic exposure at delivery as routine practice, not as a signal that anything here is being treated as risky.
Agreed: omalizumab continued at her current dose and interval through the pregnancy, with the pediatric team informed of biologic exposure at delivery as standard practice, and asthma control monitored at each obstetric visit alongside routine prenatal care.
Not agreed: whether to increase monitoring frequency specifically in the third trimester given the expected rise in placental IgG transfer. The pharmacologist sees no specific indication to change monitoring based on a pharmacokinetic fact with no associated harm signal; the MFM specialist prefers an added third-trimester check purely for reassurance given how much transfer increases at that stage, independent of whether any specific finding is expected. Left as the MFM specialist's own discretion going forward.